Vertex Pharmaceuticals Vertex Pharmaceuticals (NASDAQ: VRTX) has climbed more than 40% since the start of the year, and for good reason. Across industries, headwinds such as rising inflation and general economic woes are weighing on companies and stock performance. And for the fiscal 2022 full year, the company recently reported a 24% decrease in diluted earnings per share on a GAAP basis.